EU regulator weighs using smallpox vaccine to address monkeypox outbreaks – GLOBAL

June 28, 2022

The European Medicines Agency says it will begin reviewing data to decide if a smallpox vaccine made by the pharmaceutical company Bavarian Nordic might also be authorized for monkeypox, amid a growing outbreak of the disease across the continent.

In a statement on Tuesday, the EU drug regulator noted that the vaccine, known as Imvanex in Europe but sold as Jynneos in the U.S., is already cleared for use against monkeypox by American regulators.

In Europe, the vaccine is only authorized in adults for the prevention of smallpox, which is related to monkeypox.

“The decision to start this review is based on results from laboratory studies suggesting that the vaccine triggers the production of antibodies that target the monkeypox virus,” the EMA said. The regulator said that supplies of the vaccine are currently very limited in Europe.

Read more: https://globalnews.ca/news/8952608/monkeypox-vaccine-eu-regulator-review/